| Article 2 (Standards for Research and Development Institutes of Medical Services) |
| 1. | A research and development institute of medical services shall at all times have one researcher who directly conduct research and development of medical services and do not concurrently engage in other duties, such as sales or business, aside from the duties of research and development of medical services; |
| 2. | A research and development institute of medical services shall have the following facilities to independently conduct research and development of medical services: |
| (a) | At least one laboratory; |
| (b) | Research equipment that researchers may individually use, such as experimental apparatus and electronic data storage media; |
| (c) | Ancillary facilities, such as air purifying and heating and cooling equipment. |
| (2) | Detailed standards for the researchers and facilities of a research and development institute of medical services under paragraph (1) shall be determined and publicly notified by the Minister of Health and Welfare in consideration of the kinds of research and development institutes of medical services, the details and characteristics of research and development of medical services, and other factors. <Amended on Mar. 15, 2010> |
| Article 3 (Contents of Plans to Develop High-Tech Medical Complexes) |
| 1. | Plans to cooperate with institutes for research and development of medical services in Korea and overseas; |
| 2. | Matters deemed necessary by the committee on high-tech medical complexes established under Article 27 of the Act (hereinafter referred to as "committee on high-tech medical complexes"). |
| Article 4 (Requirements for Site Selection for High-Tech Medical Complexes) |
"Matters specified by Presidential Decree" in Article 5 (2) 6 of the Act means impact on the balanced development of the National Land.
| Article 5 (Detailed Standards for Site Selection) |
| (1) | Standards for outstanding researchers, research and development institutes of medical services, and medical institutions referred to in Article 5 (3) of the Act are as follows: |
| 1. | Outstanding researchers: A researcher having abundant experience and specialized knowledge in research and development of medical services, such as publishing research papers on research and development of medical services in Korea and overseas or participating in medical research and development projects; |
| 2. | Outstanding research and development institutes of medical services: A research and development institute of medical services having a track record of conducting research and development of medical services, such as a high ratio of medical research and development funds to total sales, or holding Korean or foreign patents on research and development of medical services; |
| 3. | Outstanding medical institutions: A medical institution having a track record of performing clinical tests entrusted by Korean or foreign enterprises, etc. |
| (2) | Detailed standards concerning the feasibility of invitation and settlement, the level of clustering and connectivity of outstanding research and development institutes of medical services, and other relevant matters referred to in Article 5 (3) of the Act are as follows: <Amended on Nov. 21, 2017; Oct. 23, 2018> |
| 1. | Feasibility of invitation and settlement: That conditions for settlement, such as dwelling, medical services, education, environment, culture, and transportation with which outstanding researchers and research and development institutes of medical services under paragraph (1) 1 and 2 can be invited, shall be met, or that the improvement of conditions for settlement while a high-tech medical complex is being developed shall be highly feasible; |
| 2. | Level of clustering of outstanding research and development institutes of medical services: That there shall be many outstanding research and development institutes of medical services and outstanding medical institutions in an area specified by the committee on high-tech medical complexes, including places prearranged for high-tech medical complexes; |
| 3. | Degree of connectivity with outstanding research and development institutes of medical services: That there shall be a sound track record of conducting research and development, research activities, etc. through cooperation among research and development institutes of medical services in Korea and overseas or exchanges therewith, such as a large number of concluded agreements; |
| 4. | Details of support by local governments: That there shall be a high level of financial and tax assistance by the Special Metropolitan City, Metropolitan Cities, Special Self-Governing City, Dos, and Special Self-Governing Province to the research and development institutes of medical services and medical innovations foundations (hereinafter referred to as "foundation") established under Article 11 of the Act, that take occupancy in a high-tech medical complex, with a high degree of support to facilitate the active research and development of medical services; |
| 5. | Availability of sites: That sites are available and are efficient in light of regulation on the use of land, price of land, etc.; |
| 6. | Impact on the balanced development of national land: That there shall be substantial impact on the balanced development of the capital area and other areas, and large cities and small and medium-sized cities. |
| (3) | Matters necessary for the specific scope of detailed standards for the site selection of high-tech medical complexes under paragraphs (1) and (2), evaluation thereof and other matters shall be determined by the Minister of Health and Welfare after deliberation by the committee on high-tech medical complexes. <Amended on Dec. 31, 2008; Mar. 15, 2010> |
| Article 6 (Public Notification of Designation of High-Tech Medical Complexes or Cancellation thereof) |
| (1) | If the site for a high-tech medical complex is selected pursuant to Article 6 (1) of the Act, the Minister of Health and Welfare shall publicly notify the details of designation of the high-tech medical complex, including following matters: <Amended on Mar. 15, 2010> |
| 1. | Name, location and size of the high-tech medical complex; |
| 2. | Purpose of designating the high-tech medical complex; |
| 3. | Main facilities to be established in the high-tech medical complex; |
| 4. | Other matters deemed necessary by the committee on high-tech medical complexes. |
| (2) | If the Minister of Health and Welfare fully or partially cancel the designation of a high-tech medical complex pursuant to Article 8 (2) of the Act, he/she shall publicly notify the grounds for cancellation and the date of cancellation (including changes among the details publicly notified under paragraph (1) if the designation is partially cancelled). <Amended on Mar. 15, 2010> |
| Article 7 (Submission of Plans to Advance High-Tech Medical Complexes) |
Every five years, the head of an operating agency referred to in Article 10 (1) of the Act shall submit a plan to carry out matters under his/her jurisdiction, that are necessary for advancing a high-tech medical complex by not later than three months before the commencement of the fiscal year defined in Article 2 of the National Finance Act. <Amended on Dec. 31, 2008; Mar. 15, 2010; Oct. 23, 2018>
| Article 8 (Matters to be Included in Comprehensive Plans) |
| 1. | Matters concerning facilitating investment in medical research and development from Korea and overseas; |
| 2. | Matters concerning training human resources, such as research personnel and human resources for technical training; |
| 3. | Other matters deemed necessary by the committee on high-tech medical complexes. |
| Article 9 (Centers for Supporting Research and Development of Medical Services) |
"Centers prescribed by Presidential Decree, such as a center for managing resources related to research and development of medical services" in Article 11 (4) 5 of the Act means any of the following: <Amended on Mar. 15, 2010; Oct. 23, 2018> | 1. | A center managing resources, such as organic substances and chemical compounds necessary for research and development of medical services; |
| 2. | A center recognized by the Minister of Health and Welfare, which facilitates the provision of information on Korean or foreign patents, transaction of technology, development of designs, etc. to commercialize research and development of medical services and the outcomes thereof. |
[This Article Wholly Amended on Oct. 23, 2018]
| Article 10 Deleted. <Oct. 23, 2018> |
| Article 11 (Eligibility for Fund for Establishment and Promotion of SMEs and Startups) |
| (1) | Those eligible for the Fund for the Establishment and Promotion of SMEs and Startups referred to in Article 13 (1) of the Act are as follows: <Amended on Oct. 23, 2018; Oct. 29, 2019> |
| 1. | Research and development of medical services concerning medicines and medical appliances conducted by research and development institutes of medical services and foundations that have taken occupancy in a high-tech medical complex and support projects directly related thereto; |
| 2. | Research and development of medical services conducted by a medical institution designated pursuant to Article 21 (1) of the Act. |
| (2) | In either of the following circumstances, the principal and interest of a loan can be fully or partially exempted or reduced pursuant to Article 13 (2) of the Act: |
| 1. | Where, as a result of the implementation of a medical research and development project, the project is determined to be economically infeasible or continuing medical research is deemed impracticable; |
| 2. | Where fully or partially repaying the principal and interest of a loan is impossible not for managerial reasons but for inevitable ones, such as a sudden change in economic circumstances in Korea and overseas, in the process of performing a medical research and development project. |
[Title Amended on Oct. 29, 2019]
| Article 12 (Calculation of Charges for Commercial Use or Loan of the State-owned or Public Property, Charges on Profit therefrom, etc.) |
| Article 13 (Methods of Paying Price for Purchase of State or Public Property) |
| (1) | The due date for paying the purchase price of State or public property under Article 18 (5) of the Act may be extended within one year, or such purchase price may be paid in installments within 20 years. |
| (2) | Where the due date for payment is extended or installment payments are made pursuant to paragraph (1), interest on the purchase price shall not exceed 4/1,000 per annum. |
| Article 14 (Exceptions to Period of Sojourn of Foreigners) |
| (1) | The upper limit on the period of sojourn that can be granted at one time for the status of sojourn corresponding to professorship visa (E-1), research visa (E-3), technology transfer visa (E-4), professional employment visa (E-5), special occupation visa (E-7), trade management visa (D-9), and family visitation visa (F-1) pursuant to Article 20 of the Act shall be five years. |
| Article 15 (Composition and Operation of Sub-Committee for High-Tech Medical Complexes) |
| (1) | The sub-committee for high-tech medical complexes established under the National Bioethics Committee (hereinafter referred to as the "sub-committee") prescribed by Article 25 (1) of the Act shall consist of up to seven members, including one chairperson, from among the following persons: <Amended on Mar. 15, 2010; Mar. 23, 2013; Jul. 26, 2017> |
| 1. | The Minister of Science and ICT, the Minister of Trade, Industry and Energy, and the Minister of Health and Welfare; |
| (2) | The chairperson of the sub-committee (hereafter in this Article referred to as "chairperson") and its members shall be appointed or commissioned by the chairperson of the National Bioethics Committee prescribed by Article 7 of the Bioethics and Safety Act (hereinafter referred to as the “National Committee”). <Amended on Mar. 23, 2013; May 10, 2016> |
| (4) | The chairperson of the National Committee may dismiss a commissioned member of the sub-committee who falls under any of the following cases: <Newly Inserted on May 10, 2016> |
| 1. | Where he/she becomes incapable of performing his/her duties due to mental or physical disability; |
| 2. | Where he/she engages in any misconduct in connection with his/her duties; |
| 3. | Where he/she is deemed unsuitable as a member due to neglect of a duty, loss of dignity, or any other reason; |
| 4. | Where he/she voluntarily admits that it is impracticable for him/her to perform his/her duties. |
| (5) | The chairperson shall represent the sub-committee and have general supervision and control of its affairs. |
| (6) | Where the chairperson is unable to perform his/her duties due to any unavoidable cause, a member designated in advance by the chairperson shall act on behalf of the chairperson. |
| (7) | The chairperson shall convene a meeting of the sub-committee and preside over such meeting in any of the following cases: <Amended on Mar. 15, 2010; May 10, 2016> |
| 1. | If requested by the Minister of Health and Welfare or the chairperson; |
| 2. | If requested by at least three incumbent members of the sub-committee; |
| 3. | If deemed necessary by the chairperson of the National Committee. |
| (8) | If the chairperson intends to convene a meeting, he/she shall notify the members of the date, time, venue, agenda, etc. for the meeting, by not later than seven days before the meeting: Provided, That if there is any unavoidable cause, he/she may notify the members of such matters by not later than the day before the meeting. |
| (9) | A majority of all incumbent members of the sub-committee shall constitute a quorum, and any decision thereof shall require the concurring vote of at least a majority of those present. |
| (10) | Where deemed necessary for deliberation, the chairperson may request relevant agencies, organizations, etc. to submit data or opinions. |
| (11) | Matters deliberated on by the sub-committee shall be reported to the National Committee. <Amended on Mar. 23, 2013; May 10, 2016> |
| (12) | An executive secretary shall be appointed to the sub-committee to handle the administrative affairs of the sub-committee. In such case, the chairperson of a foundation shall become the executive secretary. <Amended on Oct. 23, 2018> |
| (13) | Except as otherwise expressly provided for in this Decree, matters concerning the operation of the sub-committee shall be determined by the chairperson following resolution by the sub-committee. |
| Article 16 (Matters to be Deliberated on by Institutional Bioethics Committee) |
| Article 17 (Composition and Operation of Institutional Committee) |
| (1) | An institutional committee shall consist of at least five members, including one chairperson, and the following persons shall be included therein: <Amended on Oct. 23, 2018> |
| 1. | One employee of a foundation; |
| 2. | One person working in the field of bioscience or medical science; |
| 3. | Two persons who are not working for an agency or organization in a high-tech medical complex. |
| (2) | The chairperson of an institutional committee shall be elected by mutual vote from among its members, and its members shall be commissioned by the head of a medical institution designated by the Minister of Health and Welfare pursuant to Article 21 (1) of the Act. <Amended on Mar. 15, 2010> |
| (3) | The term of office of the members shall be two years, which is renewable for only one further term. |
| (4) | The chairperson shall represent the relevant institutional committee, and have general supervision and control of its affairs. |
| (5) | If the chairperson is unable to perform his/her duties due to any unavoidable cause, a member designated in advance by the chairperson shall act on behalf of the chairperson. |
| (6) | The chairperson of an institutional committee shall convene a meeting of the institutional committee and chair such meeting in any of the following cases: <Amended on Mar. 23, 2013> |
| 1. | If requested by the head of an agency; |
| 2. | If requested by at least 1/3 of all incumbent members of the institutional committee; |
| 3. | If deemed necessary by the chairperson of the institutional committee. |
| (7) | Where the research, development, or use of bioscience and technology conducted in a high-tech medical complex seriously compromise or is likely to compromise bioethics or safety, the chairperson shall, without delay, convene a meeting and report the results of the meeting to the Minister of Health and Welfare. <Amended on Mar. 15, 2010> |
| (8) | A majority of all incumbent members of an institutional committee shall constitute a quorum, and any decision thereof shall require the concurring vote of at least a majority of those present. In such case, at least one member falling under paragraph (1) 3 shall attend the meeting. |
| (9) | No member involved in the research, development, or use of bioscience and technology to be deliberated on under Article 16 shall participate in deliberation on any agenda item regarding such research, development, or use of bioscience and technology. |
| (10) | Where deemed necessary for deliberation by an institutional committee, the chairperson may request relevant agencies, organizations, etc. to submit data or opinions. |
| (11) | An institutional committee shall prepare and keep documents in which the list and qualifications of members and the meeting minutes of the institutional committee are recorded. |
| (12) | Except as otherwise expressly provided for in this Decree, matters concerning the operation of an institutional committee shall be determined by the chairperson following resolution by the institutional committee. |
| Article 17-2 (Installation of Production Facilities of Resident Research and Development Institute of Medical Service) |
| (1) | “Small-scale production facilities prescribed by Presidential Decree” in Article 26-2 (1) of the Act means production facilities the gross floor area of which does not exceed 5,000 square meters. <Amended on Aug. 24, 2021> |
| (2) | A resident research and development institute of medical services which intends to obtain approval for installation of production facilities under the former part of Article 26-2 (2) of the Act shall submit to the Minister of Health and Welfare an application for installment prescribed by Ordinance of the Ministry of Health and Welfare (including an electronic application form) with the following documents attached: |
| 1. | Detailed statement of production facilities and items produced; |
| 2. | Plan for production operation of items produced; |
| 3. | Other documents the Minister of Health and Welfare deems necessary including research performance of resident research and development institutes of medical service. |
| (3) | When the Minister of Health and Welfare receives an application pursuant to paragraph (2), he/she shall decide whether to approve the application, giving consideration to the following, and inform the applicant of the decision: |
| 1. | Impact on invigoration of research and development of medical service; |
| 2. | Effect related to commercialization of research results; |
| 3. | Impact on development of technology for health and medical services or others. |
| (4) | A person who intends to obtain approval for adding items produced or approval for change under the latter part of Article 26-2 (2) of the Act shall submit an application for approval for change (including an electronic application form) with attaching documents of changes (including electronic document) to the Minister of Health and Welfare. In such case, paragraph (3) shall mutatis mutandis to process of application for approval for change. |
| (5) | Matters other than those specified in paragraphs (1) through (4) necessary for procedures and methods of approval for installation of production facilities and approval for change shall be determined by Ordinance of the Ministry of Health and Welfare. |
[This Article Newly Inserted on Jul. 6, 2016]
| Article 18 (Composition and Operation of Committee on High-Tech Medical Complexes) |
| (1) | "Vice Minister, Vice Administrator or any other equivalent public official of each competent central administrative agency prescribed by Presidential Decree" in Article 28 (2) of the Act means the Vice Minister of Economy and Finance, the Vice Minister of Science and ICT, the Vice Minister of Justice, the Vice Minister of Trade, Industry and Energy, the Vice Minister of Land, Infrastructure and Transport, and the Vice Minister of Food and Drug Safety. In such cases, if two or more Vice Ministers exist in any agency, the Vice Minister designated by the head of the relevant agency shall serve as a member: <Amended on Oct. 29, 2019> |
| (2) | The term of office of the commissioned members under Article 28 (3) of the Act shall be two years, which is renewable for only one further term. |
| (3) | The chairperson may dismiss a commissioned member under Article 28 (3) of the Act, if the member falls under any of the following cases: <Newly Inserted on May 10, 2016> |
| 1. | Where he/she becomes incapable of performing his/her duties due to mental or physical disability; |
| 2. | Where he/she engages in any misconduct in connection with his/her duties; |
| 3. | Where he/she is deemed unsuitable as a member due to neglect of a duty, loss of dignity, or any other reason; |
| 4. | Where he/she voluntarily admits that it is impracticable for him/her to perform his/her duties. |
| (4) | The chairperson shall represent the committee on high-tech medical complexes, and have general supervision and control of its affairs. |
| (5) | If the chairperson is unable to perform his/her duties due to any unavoidable cause, a member shall act on behalf of the chairperson in accordance with the order prescribed in paragraph (1). |
| (6) | If requested by at least 1/3 of the incumbent members of the committee on high-tech medical complexes or if deemed necessary by the chairperson, the chairperson shall convene a meeting of the committee on high-tech medical complexes and chair such meeting. |
| (7) | If the chairperson intends to convene a meeting, he/she shall notify members of the date, time, venue, agenda, etc. for the meeting in writing by not later than seven days before the meeting: Provided, That if there is any unavoidable cause, he/she may notify members of such matters by not later than the day before the meeting. |
| (8) | A majority of the members of the committee on high-tech medical complexes shall constitute a quorum, and any decision thereof shall require the concurring vote of at least a majority of those present. |
| (9) | Where necessary for deliberating on the following matters concerning the operation of a high-tech medical complex, a sub-committee consisting of six members, including three commissioned members of the committee on high-tech medical complexes, may be operated; in such case, matters deliberated on by the sub-committee shall be reported to the committee on high-tech medical complexes: <Amended on May 10, 2016; Oct. 23, 2018; Oct. 29, 2019> |
| 1. | Matters concerning the secretariat established in the Ministry of Health and Welfare under Article 28 (6) of the Act (hereinafter referred to as "secretariat"); |
| 2. | Civil complaints or clerical works in need of prompt handling; |
| 3. | Matters requested by the committee on high-tech medical complexes for prior deliberation. |
| (10) | If necessary, the Vice Minister, Vice Administrator or any other equivalent public official of a central administrative agency, other than an ex officio member referred to in Article 28 (2) of the Act, may attend a meeting of the committee on high-tech medical complexes and make a statement. <Amended on May 10, 2016; Oct. 29, 2019> |
| (11) | Except as provided in paragraphs (1) through (10), matters necessary for the operation of the committee on high-tech medical complexes and the composition and operation of the sub-committee shall be determined by the chairperson following resolution by the committee on high-tech medical complexes. <Amended on May 10, 2016; Oct. 29, 2019> |
Members and private specialists who attend a meeting of the committee on high-tech medical complexes may be paid allowances within budgetary limits: Provided, That where a public official member attends a meeting of the committee in direction connection with his/her duties, no allowance shall be paid to him/her.
| Article 20 (Duties of Secretariat) |
| (1) | The duties performed by the secretariat shall be as follows: <Amended on Oct. 29, 2019> |
| 1. | Drafting, planning, examining, evaluating, inspecting, etc. agenda items submitted to the committee on high-tech medical complexes; |
| 2. | Managing statutes and regulations related to high-tech medical complexes; |
| 3. | Fostering high-tech medical complexes; |
| 4. | Data research, publicity, and international cooperation concerning high-tech medical complexes; |
| 5. | Managing foundations, such as evaluating the operational performance of foundations; |
| 6. | Other matters concerning efficiently managing high-tech medical complexes. |
| (2) | The executive officers and employees of corporations or organizations dispatched to the secretariat under Article 28 (7) of the Act may be paid allowances within budgetary limits. |
| (3) | Except as provided in paragraphs (1) and (2), matters necessary for the composition and operation of the secretariat shall be determined by the chairperson of the committee on high-tech medical complexes following resolution by the committee on high-tech medical complexes. |
[This Article Wholly Amended on Oct. 23, 2018]
| Article 21 (Approval for Move-in and Change) |
| (1) | A person who intends to obtain approval for move-in pursuant to Article 31 (1) of the Act shall submit to the Minister of Health and Welfare an application for approval for move-in (including an electronic application) with the following documents (including an electronic document) attached: |
| 1. | A project plan of research and development of medical service; |
| 2. | Detailed statement of research personnel and facilities under subparagraphs of Article 2 (1); |
| 3. | A plan for the use of the site to be moved in; |
| 4. | Other documents that the Minister of Health and Welfare deems necessary including research performance of an institute which has applied for approval for move-in. |
| (2) | When the Minister of Health and Welfare receives an application for approval for move-in, he/she shall decide whether to approve the application and inform the applicant of the decision: |
| 1. | The purpose of move-in and the appropriateness of a plan for research and development of medical services; |
| 2. | Feasibility of plan for the use of the site to be moved in; |
| 3. | Impact on invigoration of high-tech medical complexes. |
| (3) | A person who intends to obtain approval to change any of the following matters shall submit an application for approval for change prescribed by Ordinance of the Ministry of Health and Welfare (including an electronic application) with documents of details of the change attached to the Minister of Health and Welfare. In such case, subparagraph (2) shall mutatis mutandis to process of application of approval for change: |
| 1. | Change of the name or the representative of a research and development institute of medical services; |
| 2. | Change of location of the site for move-in; |
| 3. | Change 10/100 or more of the total area of the site for move-in; |
| 4. | Change of plan for the use of the site for move-in. |
| (4) | Except matters prescribed by paragraphs (1) through (3), details necessary for procedures and methods of approval for move-in or change shall be determined by Ordinance of the Ministry of Health and Welfare. |
[This Article Wholly Amended on Jul. 6, 2016]
| Article 22 (Delegation and Entrustment of Authority) |
| (1) | Pursuant to Article 32 (1) of the Act, the Minister of Health and Welfare shall delegate the following authority (excluding receipt of documents related to the affairs referred to in subparagraphs 1 and 2) to the competent Special Metropolitan City Mayor, Metropolitan City Mayor, Special Self-Governing City Mayor, Do Governor, or Special Self-Governing Province Governor: <Amended on Aug. 24, 2021> |
| 1. | Approval for installation or change of small-scale production facilities under Article 26-2 (2) of the Act (limited to production facilities the gross floor area of which does not exceed 3,000 square meters); |
| 3. | Order to take corrective measures, cancellation of approval for move-in, and holding of a hearing under Article 31 (3) of the Act. |
| (2) | The competent Special Metropolitan City Mayor, Metropolitan City Mayor, Special Self-Governing City Mayor, Do Governor, or Special Self-Governing Province Governor to whom authority is delegated under paragraph (1) shall submit or report data or the current status regarding handling of delegated affairs to the Minister of Health and Welfare, as prescribed by the Minister of Health and Welfare. |
| (3) | The Minister of Health and Welfare shall entrust the following affairs to foundations under Article 32 (2) of the Act: <Amended on Oct. 23, 2018> |
| 1. | Receipt of documents related to the affairs referred to in paragraph (1) 1 and 2; |
| 2. | Issuance of a written recommendation under Article 14 (2). |
[This Article Wholly Amended on Nov. 21, 2017]
ADDENDA <Presidential Decree No. 20869, Jun. 25, 2008>
Article 1 (Enforcement Date)
This Decree shall enter into force on 6/29/2008.
Articles 2 (Transitional Measures concerning Submission of First Promotional Plan)
The head of an operating agency under Article 10 (1) of the Act shall prepare a promotional plan for matters falling under his/her jurisdiction pursuant to Article 7 and submit it to the Minister of Health, Welfare and Family Affairs by not later than September 30, 2010. <Amended on Dec. 31, 2008>
ADDENDA <Presidential Decree No. 21227, Dec. 31, 2008>
This Decree shall enter into on the date of its promulgation.
ADDENDUM <Presidential Decree No. 21835, Nov. 20, 2009>
Article 1 (Enforcement Date)
This Decree shall enter into force on 11/22/2009.
Article 2 Omitted.
Article 3 Omitted.
ADDENDA <Presidential Decree No. 22075, Mar. 15, 2010>
Article 1 (Enforcement Date)
This Decree shall enter into force on March 19, 2010. (Proviso Omitted.)
Article 2 Omitted.
ADDENDA <Act No. 11690, Mar. 23, 2013>
Article 1 (Enforcement Date)
This Decree shall enter into force on the date of its promulgation. (Proviso Omitted.)
Articles 2 and 3 Omitted.
Articles 4 through 5 Omitted.
ADDENDUM <Presidential Decree No. 27129, May 10, 2016>
This Decree shall enter into on the date of its promulgation.
ADDENDA <Presidential Decree No. 27316, Jul. 6, 2016>
This Decree shall enter into force on the date of its promulgation: Provided, That the amended provisions of Article 17-2 and subparagraph 2 (a) of Article 22 shall enter into force on July 7, 2016.
ADDENDA <Act No. 14839, Jul. 26, 2017>
Article 1 (Enforcement Date)
This Decree shall enter into force on the date of its promulgation: Provided, That, from among the Presidential Decrees amended pursuant to Article 8 of the Addenda, the amendments to any Presidential Decree, which was promulgated before this Decree enters into force but the enforcement date of which has yet to arrive, shall enter into force on the enforcement date of the relevant Presidential Decree. Articles 2 through 7 Omitted.
Article 8 Omitted.
ADDENDUM <Presidential Decree No. 28441, Nov. 21, 2017>
This Decree shall enter into on the date of its promulgation.
ADDENDA <Presidential Decree No. 29163, Sep. 18, 2018>
Article 1 (Enforcement Date)
This Decree shall enter into force on 9/21/2018.
Article 2 Omitted.
Article 3 Omitted.
ADDENDUM <Presidential Decree No. 29251, Oct. 23, 2018>
This Decree shall enter into force on 10/25/2018.
ADDENDA <Presidential Decree No. 30170, Oct. 29, 2019>
Article 1 (Enforcement Date)
This Decree shall enter into force on November 1, 2019.
Article 2 Omitted.
Article 3 (Relationship to Other Statutes or Regulations)
ADDENDUM <Presidential Decree No. 31951, Aug. 24, 2021>
This Decree shall enter into force on the date of its promulgation.